Instituto Brasileiro de Controle do Cancer Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2007
NCT00926315
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Instituto Brasileiro de Controle do Cancer

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Nausea (Phase 2)

Vomiting (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 5